ST. LOUIS – Senzime, a global medical device company that specializes in neuromuscular treatment, is planning to move its US headquarters to St. Louis.
The company is preparing to move its headquarters from Boston to St. Louis and expand its US-based sales teams, according to a Jan. 17 news release.
Leaders say these changes will help Senzime meet increased market demands for its products and services.
“The relocation of our US headquarters to scalable offices in St. Louis enables more rapid, cost-effective, and sustainable shipments to hospitals across the US. We have strong financial backing, but reduced overhead expenses actually makes this US commercial expansion cost-neutral,” said Philip Siberg, CEO of Senzime.
Senzime reports its dealing with a rapid market and clinical shift. Last year, the company secured several major hospital contracts.
Senzime’s TetraGraph system is a quantitative neuromuscular monitoring system that helps hospitals meet new guidelines. Anesthesiologists at hundreds of leading hospitals across the globe use it to help improve patient safety during and after surgery.